News from Syndax Pharmaceuticals, Inc. A wide array of domestic and global news stories; news topics include politics/government, business, technology, religion, sports/entertainment, science/nature, and health/lifestyle. Articles that appear in this section may be written in English or other languages.

Latest

Aug 10, 2017, 16:05 ET Syndax Pharmaceuticals Reports Second Quarter 2017 Financial Results and Provides Clinical and Business Update

Syndax Pharmaceuticals, Inc. ("Syndax," the "Company" or "we") (Nasdaq: SNDX), a clinical stage biopharmaceutical company developing entinostat and...


Aug 03, 2017, 07:00 ET Syndax to Announce Second Quarter 2017 Financial Results and Host Conference Call and Webcast on August 10, 2017

Syndax (Nasdaq: SNDX) announced today that it will release its second quarter 2017 financial results on Thursday, August 10, 2017, after...


Jul 11, 2017, 16:05 ET Preclinical Results Support Entinostat's Role in Targeting the Tumor Microenvironment to Enhance Immune Checkpoint Therapy

Syndax Pharmaceuticals, Inc. ("Syndax," the "Company" or "we") (Nasdaq:SNDX), a clinical stage biopharmaceutical company developing entinostat and...


Jan 20, 2016, 08:00 ET Allan L. Shaw Joins Syndax Pharmaceuticals As Chief Financial Officer

Syndax Pharmaceuticals, Inc., a clinical stage biopharmaceutical company focused on developing entinostat in multiple cancer indications, announced...


Dec 03, 2015, 08:00 ET Syndax Announces Multiple Data Presentations On Entinostat At Upcoming San Antonio Breast Cancer Symposium

Syndax Pharmaceuticals, Inc., a clinical stage biopharmaceutical company focused on developing entinostat as a combination therapy in multiple...


Dec 01, 2015, 08:00 ET Syndax Announces Initiation Of Entinostat Clinical Program In Japan By Partner Kyowa Hakko Kirin

 Syndax Pharmaceuticals, Inc., a clinical stage biopharmaceutical company focused on developing entinostat as a combination therapy in multiple...


Sep 16, 2015, 08:00 ET Syndax To Present At Two Upcoming Scientific Conferences

 Syndax Pharmaceuticals, Inc., a clinical stage biopharmaceutical company focused on developing entinostat as a combination therapy in multiple...


Sep 01, 2015, 08:00 ET Michael Meyers, M.D., Ph.D., Joins Syndax Pharmaceuticals As SVP And Chief Development Officer

 Syndax Pharmaceuticals, Inc., a clinical stage biopharmaceutical company focused on developing entinostat as a combination therapy in multiple...


Feb 05, 2015, 12:00 ET Syndax to Present at 2015 BIO CEO & Investor Conference

 Syndax Pharmaceuticals, Inc., today announced that chief executive officer, Arlene Morris, will be presenting a corporate overview at the 17th...


Jan 07, 2015, 19:00 ET Kyowa Hakko Kirin and Syndax Announce an Exclusive License Agreement to Develop and Commercialize Entinostat in Japan and Korea

 Kyowa Hakko Kirin Co., Ltd., (Headquarters: Chiyoda-ku, Tokyo; president and CEO: Nobuo Hanai, "Kyowa Hakko Kirin") and Syndax...


May 27, 2014, 08:00 ET Syndax Announces Presentation of Entinostat Data in Two Posters at the 2014 American Society of Clinical Oncology (ASCO) Annual Meeting

 Syndax Pharmaceuticals, Inc., today announced that clinical trial data on entinostat will be presented in two posters during the 50th Annual...


Mar 27, 2014, 18:43 ET Syndax Files Registration Statement for Proposed Initial Public Offering

 Syndax Pharmaceuticals, Inc. today announced that it has filed a registration statement on Form S-1 with the U.S. Securities and Exchange...


Feb 13, 2014, 08:00 ET Syndax Announces NCI and FDA Reach Agreement on a Special Protocol Assessment (SPA) for the Phase 3 Trial of Entinostat in Patients with Advanced ER+ Breast Cancer

Syndax Pharmaceuticals, Inc., today announced that the Division of Cancer Treatment and Diagnosis (DCTD) of the National Cancer Institute (NCI) has...


Nov 01, 2013, 08:00 ET Syndax Promotes John S. Pallies to Chief Financial Officer and Dr. Peter Ordentlich to Chief Technology Officer

Syndax Pharmaceuticals, Inc. today announced the promotion of John S. Pallies to chief financial officer from vice president, finance and...


May 14, 2013, 08:30 ET Syndax Pharmaceuticals Announces Publication of Clinical Study Demonstrating that Entinostat Targets Resistance Pathways in Breast Cancer

 Syndax Pharmaceuticals, Inc., a late-stage oncology company focused on developing novel combination epigenetic strategies to treat cancers...


May 16, 2012, 08:30 ET Syndax Pharmaceuticals Appoints Luke Evnin, Ph.D. to Board of Directors

 Syndax Pharmaceuticals, Inc., an oncology company moving into phase 3 having completed randomized, placebo controlled phase 2 studies,...


Apr 30, 2012, 08:30 ET Syndax Pharmaceuticals Announces Publication of Entinostat Phase 2 Clinical Trial Data in Journal of Clinical Oncology

 Syndax Pharmaceuticals, Inc., a late-stage oncology company focused on the clinical development of epigenetic therapies in solid tumors,...


Apr 18, 2012, 09:53 ET Syndax Pharmaceuticals Appoints Arlene Morris as CEO

 Syndax Pharmaceuticals, Inc., an oncology company moving into phase 3 having completed randomized, placebo controlled phase 2 studies,...


Apr 09, 2012, 08:30 ET Syndax Pharmaceuticals Announces Start of Phase 1/2 Study of Entinostat in Combination with Lapatinib in HER2-Positive Metastatic Breast Cancer

 Syndax Pharmaceuticals, Inc., a clinical-stage epigenetics oncology company, announced that investigators at The University of Texas MD...


Apr 05, 2012, 08:30 ET Syndax Pharmaceuticals Appoints Arthur M. Pappas to Board of Directors

 Syndax Pharmaceuticals, Inc., a clinical-stage epigenetics oncology company, announced Arthur M. Pappas will join the board of...


Mar 29, 2012, 08:30 ET Syndax Pharmaceuticals to Present at Upcoming Conferences

 Syndax Pharmaceuticals, Inc., a clinical-stage epigenetics oncology company, announced that management will present at the following upcoming...


Feb 09, 2012, 09:00 ET Syndax Pharmaceuticals Announces Entinostat Enhanced Activity of Cancer Immunotherapies in Renal and Prostate Cancer Models

Syndax Pharmaceuticals, Inc., a clinical-stage epigenetics oncology company, announced that scientists at Roswell Park Cancer Institute have...


Feb 07, 2012, 08:30 ET Syndax Pharmaceuticals to Present at Upcoming Conferences

 Syndax Pharmaceuticals, Inc., a late-stage epigenetics oncology company, announced that management will present at the following upcoming...


Dec 11, 2011, 21:00 ET Entinostat Demonstrates Activity in Hodgkin's Lymphoma

Syndax Pharmaceuticals, Inc. announced today that data from ENGAGE 501, a multicenter, phase 2 study, demonstrated entinostat, a novel, oral small...


Dec 07, 2011, 18:00 ET Survival Benefit With Syndax Pharmaceuticals' Entinostat Maintained in Women with Advanced Breast Cancer

 Syndax Pharmaceuticals, Inc. announced today that, with a 23-month patient follow up of ENCORE 301, a multicenter, randomized,...